Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nanosonics Limited ( (AU:NAN) ) has shared an announcement.
JPMorgan Chase & Co. and its affiliates have notified Nanosonics that they have ceased to be a substantial holder in the company as of 8 April 2026. The change reflects reductions and reallocations across various JPMorgan entities, including securities lending, proprietary trading, and rehypothecation activities.
The exit of JPMorgan as a substantial shareholder may modestly shift Nanosonics’ share register, but it does not signal any direct change to the company’s operations or strategy. For investors, the move highlights ongoing institutional portfolio adjustments in the stock, rather than a company-specific event, and may affect liquidity and ownership concentration at the margin.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.55 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
More about Nanosonics Limited
Nanosonics Limited is an Australian medical technology company focused on infection prevention. The company is best known for its ultrasound probe disinfection systems and related consumables, targeting hospitals and healthcare providers seeking to improve sterilisation standards and reduce healthcare-associated infections.
YTD Price Performance: -6.30%
Average Trading Volume: 760,722
Technical Sentiment Signal: Sell
Current Market Cap: A$1.13B
Find detailed analytics on NAN stock on TipRanks’ Stock Analysis page.